Creutzfeldt-Jakob disease - Treatment with human pituitary gonadotrophins Factor
Last reviewed for CCPS 15 May 1998.
Preliminary questions [16284]
16374 there is some evidence that treatment with human pituitary gonadotrophins may be a factor in the development of the condition under consideration.
1169 — the veteran is a woman.
the veteran has had treatment with human pituitary gonadotrophins at some time. the veteran had treatment with human pituitary gonadotrophins before the clinical onset of Creutzfeldt-Jakob disease.16300 — the veteran has established the causal connection between the treatment with human pituitary gonadotrophins and VEA service for Creutzfeldt-Jakob disease.
16301 — the veteran has established the causal connection between the treatment with human pituitary gonadotrophins and operational service for the clinical onset of Creutzfeldt-Jakob disease.
or
16302 — the veteran has established the causal connection between the treatment with human pituitary gonadotrophins and eligible service for the clinical onset of Creutzfeldt-Jakob disease.
Clinical onset and operational service [16301]
the veteran had treatment with human pituitary gonadotrophins before the clinical onset of Creutzfeldt-Jakob disease on operational service.or
the treatment with human pituitary gonadotrophins before the clinical onset of Creutzfeldt-Jakob disease was for an illness or injury which is identifiable.16303 — the identified illness or injury for which treatment with human pituitary gonadotrophins was given is causally related to operational service.
Clinical onset and eligible service [16302]
the treatment with human pituitary gonadotrophins before the clinical onset of Creutzfeldt-Jakob disease was for an illness or injury which is identifiable.16304 — the identified illness or injury for which treatment with human pituitary gonadotrophins was given is causally related to eligible service.